Biomarkers in predicting cardiovascular risk: new prospects of troponin I

A. V. Kontsevaya; A. О. Myrzamatova; O. M. Drapkina

doi:10.15829/1728-8800-2020-2584

Biomarkers in predicting cardiovascular risk: new prospects of troponin I

A. V. Kontsevaya, A. О. Myrzamatova, O. M. Drapkina

https://doi.org/10.15829/1728-8800-2020-2584

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Risk stratification is an important aspect of effective control of cardiovascular diseases. Risk scores based on conventional risk factors did not solve the stratification problem completely due to a number of factors. One way to increase the accuracy of predicting cardiovascular risk may be to supplement conventional scores with cardiovascular biomarkers. Cardiac troponins are the most reliable cardiovascular biomarkers in the diagnosis of acute myocardial infarction. However, recent studies have shown that they have the potential to use as an addition to cardiovascular risk stratification scores. Cardiac troponins meet the requirements for new biomarkers: cardiospecificity, prognostic value, change in levels in response to risk reduction actions, evidence value, economic efficiency. A large number of population studies demonstrate the association of elevated levels of cardiac troponin I with adverse cardiovascular events. To assess the prospects of supplementing conventional risk scores with new biomarkers, including troponin I, the study of the role of biomarkers in cardiovascular risk prediction in men and women of working age is started in Russia.

Keywords

cardiovascular risk, biomarkers, troponins, troponin I

References

1. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287-323. https://doi.org/10.1016/S0140-6736(15)00128-2.

2. Wilson P, D’Agostino R, Levy D. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.

3. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 2003;24:987-1003. https://doi.org/10.1016/s0195-668x(03)00114-3.

4. Hippisley-Cox C, Coupland Y. Vinogradova. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475-82. https://doi.org/10.1136/bmj.39609.449676.25.

5. Hajifathalian K, Ueda P, Lu Y. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015;3(5):339-55. https://doi.org/10.1016/S2213-8587(15)00081-9.

6. Hozawa A, Folsom AR, Sharrett AR, et al. Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects-atherosclerosis risk in communities study. Arch Intern Med. 2007;167(6):573-9.

7. Ajani UA, Ford ES. Has the risk for coronary heart disease changed among US adults. JACC. 2006;48:1177-82. https://doi.org/10.1016/j.jacc.2006.05.055.

8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:130. https://doi.org/10.1056/NEJM199511163332001.

9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344;8934:1383-9. https://doi.org/10.1016/S0140-6736(94)90566-5.

10. LaRosa JC, Grundy SM. Treating to New Targets (TNT) Investigators, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. https://doi.org/10.1056/NEJMoa050461.

11. Ahmad T, Fiuzat M, Felker GM, O’Connor C. Novel biomarkers in chronic heart failure. Nat Rev Cardiol. 2012;9:347-59. https://doi.org/10.1038/nrcardio.2012.37.

12. Qu W, Si S, Sun L, et al. Construction of a microRNA associated feed forward loop network that identifies regulators of cardiac hypertrophy and acute myocardial infarction. Int J Mol Med. 2018;42(4):2062-70. https://doi.org/10.3892/ijmm.2018.3790.

13. Kremneva LV. The value of copeptin for the diagnosis of myocardial infarction. Russian Journal of Cardiology. 2017;22(11):93-7. (In Russ.) https://doi.org/10.15829/1560-4071-2017-11-93-97.

14. Krikunova OV, Viskov RV. Cardiac troponins in the practice of a physician. M. MEDpress-inform, 2016. 240 p. (In Russ.) ISBN 978-5-00030-0.

15. Saprygin DB. Biomarkers: new clinical opportunities and a role in understanding the mechanisms of development of cardiac pathology. IFCC Word Lab and Euro Med. Lab. 2011;5(15-19):69- 70. (In Russ.)

16. Parkhomenko AN, Irkin OI, Lutay YaM. The role of biological markers in emergency cardiology. Emergency medicine. 2011;7- 8(38-39):46-54. (In Russ.) https://doi.org/10.20538/1682-0363-2018-4-264-280.

17. Vazques V, Varon J. From molecular cardiology to emergency medical practice: the role of inflammatory markers. The American Journal of Emergency Medicine. 2012;30(7):1210-11. https://doi.org/10.1016/j.ajem.2011.07.020.

18. Lee HS, Cross SJ. Patients with suspected myocardial infarction who present with ST depression. Lancet. 1993;342:1204-7. https://doi.org/10.1016/0140-6736(93)92186-W.

19. Velkov VV. C-reactive protein - in the laboratory diagnosis of acute inflammation and in assessing the risks of vascular pathologies. Clinical and laboratory concilium. Scientific and practical Journal. 2008;2(21):37-48. (In Russ.)

20. Farmakis D, Mueller C, Apple FS. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. European Heart J. 2020; ehaa083. https://doi.org/10.1093/eurheartj/ehaa083.

21. Anderson JL, Adams CD, Antman EM. Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association. Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2008;51;9:974. https://doi.org/10.1016/j.jacc.2007.02.013.

22. Than M, Cullen L, Aldous S, et al. 2-Hour Accelerated Diagnostic Protocol to Assess Patients with Chest Pain Symptoms Using Contemporary Troponins as the Only Biomarker. J Am Coll Cardiol. 2012;59;23:2091-8. https://doi.org/10.1016/j.jacc.2012.02.035.

23. Kvisvik B, Mørkrid L, Røsjø H, et al. Prognosis in ACS highsensitivity troponin T vs I in acute coronary syndrome: prediction of significant coronary lesions and longterm prognosis. Clin Chem. 2017;63;2:552-62. https://doi.org/10.1373/clinchem.2016.261107.

24. McCarthy CP, McEvoy JW, Januzzi JL Jr. Biomarkers in stable coronary artery disease. Am Heart J. 2018;196:82-96. https://doi.org/10.1016/j.ahj.2017.10.016.

25. Farmakis D, Mantzourani M, Filippatos G. Anthracycline-induced cardiomyopathy: secrets and lies. Eur J Heart Fail. 2018;20:907-9. https://doi.org/10.1002/ejhf.1172.

26. Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med. 2014;161;7:491-501. https://doi.org/10.7326/M14-0743.

27. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503-12. https://doi.org/10.1001/jama.2010.1768.

28. Ford I, Shah AS, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016;68:2719-28. https://doi.org/10.1016/j.jacc.2016.10.020.

29. Sigurdardottir F, Lyngbakken M, Holmen O, et al. Relative Prognostic Value of Cardiac Troponin I and C-Reactive Protein in the General Population (from the Nord-Trøndelag Health [HUNT] Study). Am J Cardiol. 2018;121;8:949-55. https://doi.org/10.1016/j.amjcard.2018.01.004.

30. Blankenberg S, Salomaa V, Makarova N. BiomarCaRE Investigators. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016;37: 2428-37. https://doi.org/10.1093/eurheartj/ehw172.

31. Makarova N. Health economic evaluation of using high sensitivity troponin I for cardiovascular risk prediction in the BiomarCaRE cohort. Clin Chim Acta. 2019;493:S768-9. https://doi.org/10.1016/j.cca.2019.03.672.

32. Everett BM, Zeller T, Glynn RJ, et al. High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention impact of statin therapy. Circulation. 2015;131:1851-60. https://doi.org/10.1161/CIRCULATIONAHA.114.014522.

33. Welsh P, Preiss D, Hayward C, et al. Cardiac Troponin T and Troponin I in the General Population: Comparing and Contrasting their Genetic Determinants and Associations with Outcomes. Circulation. 2019;139;24:2754-64. https://doi.org/10.1161/CIRCULATIONAHA.118.038529.

34. Zeller T, Tunstall-Pedoe H, Saarela O, the MORGAM Investigators. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J. 2014;35;5:271-81. https://doi.org/10.1093/eurheartj/eht406.

35. Thorsteinsdottir I, Aspelund T, Gudmundsson E. High-Sensitivity cardiac troponin I is a strong predictor of cardiovascular events and mortality in the AGES-Reykjavik community-based cohort of older individuals. Clin Chem. 2016;62:623-30. https://doi.org/10.1373/clinchem.2015.250811.

36. Apple FS, Steffen LM, Pearce LA. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota heart survey. Clin Chem. 2012;58:930-5. https://doi.org/10.1373/clinchem.2011.179176.

37. Jia X, Sun W, Hoogeveen RC, et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation. 2019;139:2642-53. https://doi.org/10.1161/CIRCULATIONAHA.118.038772.

38. Willeit P, Welsh P, Evans JDW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes. J Am Coll Cardiol. 2017;70;5:558-68. https://doi.org/10.1016/j.jacc.2017.05.062.

39. Ershova AI, Meshkov AN, Deev AD, et al. Atherosclerotic plaque in the carotid arteries as a marker of the risk of cardiovascular events in the middle-aged population. Cardiovascular Therapy and Prevention. 2018;17(4):34-9. (In Russ.) https://doi.org/10.15829/1728-8800-2018-4-34-39.

For citations:

Kontsevaya A.V., Myrzamatova A.О., Drapkina O.M. Biomarkers in predicting cardiovascular risk: new prospects of troponin I. Cardiovascular Therapy and Prevention. 2020;19(3):2584. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2584

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

Cardiovascular Therapy and Prevention

Biomarkers in predicting cardiovascular risk: new prospects of troponin I

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

User

Cardiovascular Therapy and Prevention

Biomarkers in predicting cardiovascular risk: new prospects of troponin I

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy